Johnson & Johnson
- Last sale
- Nov 12, 2026 · +1.15%
- Market cap
- $682.62B
- 2.41B shares
- Filings
- 1,064
Q3 2026+6.0% FY25 yoy
Q3 2026+90.6% FY25 yoy
Q1 2015+31.6% FY14 yoy
Q3 2026derived−0.7% FY25 yoy
Q3 2026+90.5% FY25 yoy
Q3 2026−18.2% FY25 yoy
- $682.62B
- 42.4×
- 6.9×
- 8.4×
- 3.02%
- —
Twelve months to Sep 27, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-28 | $94,193,000,000 | reported | |
| FY 2024 | 2024-12-29 | $88,821,000,000 | reported | |
| FY 2023 | 2023-12-31 | $85,159,000,000 | reported | |
| FY 2022 | 2023-01-01 | $79,990,000,000 revised | reported | |
| FY 2021 | 2022-01-02 | $78,740,000,000 revised | reported | |
| FY 2020 | 2021-01-03 | $82,584,000,000 | reported | |
| FY 2019 | 2019-12-29 | $82,059,000,000 | reported | |
| FY 2018 | 2018-12-30 | $81,581,000,000 | reported | |
| FY 2017 | 2017-12-31 | $76,450,000,000 | reported | |
| FY 2016 | 2017-01-01 | $71,890,000,000 | reported | |
| FY 2015 | 2016-01-03 | $70,074,000,000 | reported | |
| FY 2014 | 2014-12-28 | $74,331,000,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $5.95B | $5.95B | $5.14 | 2.41B sh | +0.1% | 30.2% |
| FY2024 | — | $2.43B | $2.43B | $4.91 | 2.41B sh | −0.0% | 12.3% |
| FY2023 | — | $5.05B | $5.05B | $4.70 | 2.41B sh | −7.5% | 27.7% |
| FY2022 | — | $6.04B | $6.04B | $4.45 | 2.60B sh | −1.0% | 35.1% |
| FY2021 | — | $3.46B | $3.46B | $4.19 | 2.63B sh | +0.0% | 17.5% |
Segments
LineFY2025ShareChange
Innovative Medicine$60.40B64%+6.0%
MedTech$33.79B36%+6.1%
Consumer Health———
Medical Devices———
Pharmaceutical———
Total$94.19B
Pharmaceutical preparations
Johnson & Johnson is the largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
JNJJohnson & Johnson (this company)$94.2B6.0%28.5%$682.6B
LLYEli Lilly & Co$65.2B44.7%31.7%$1.3TMRKMerck & Co., Inc.$65.0B1.3%28.1%$362.3BPFEPfizer Inc$62.6B1.6%12.4%$164.3BABBVAbbVie Inc.$61.2B8.6%6.9%$520.5BAZNAstraZeneca PLC$58.7B8.6%17.4%—BMYBristol Myers Squibb Co$48.2B0.2%14.6%$127.4BABTAbbott Laboratories$44.3B5.7%14.7%$185.8BUPCUniverse Pharmaceuticals INC$17.9B22.4%20.6%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Johnson & Johnson · CIK 200406 · Engraved from SEC EDGAR